ketorolac ophthalmic
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
128
Go to page
1
2
3
4
5
6
July 29, 2026
Central Macular Thickness, Subfoveal Choroidal Thickness, and Choroidal Vascularity Index After Phacoemulsification: Bromfenac versus Ketorolac.
(PubMed, Korean J Ophthalmol)
- "This retrospective cohort study included 105 eyes (47 in the ketorolac group and 58 in the bromfenac group) that underwent uncomplicated phacoemulsification...Prophylactic bromfenac and ketorolac demonstrated comparable overall efficacy in managing postoperative inflammation following cataract surgery. In this exploratory study, bromfenac maintenance therapy was associated with smaller postoperative CVI changes, suggesting a potential role for continued NSAID use in modulating early choroidal microvascular responses."
Journal • Cataract • Inflammation • Macular Edema • Ophthalmology
July 09, 2026
INSPIRE: INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study
(clinicaltrials.gov)
- P1 | N=164 | Completed | Sponsor: Stephen J. Kim, MD | Active, not recruiting ➔ Completed
Trial completion • Diabetic Retinopathy • Retinal Disorders • CXCL8
June 06, 2026
Levofloxacin/ketorolac combination versus levofloxacin alone for topically treating moderate-severe acute bacterial conjunctivitis: a randomized controlled trial.
(PubMed, Graefes Arch Clin Exp Ophthalmol)
- P2 | "The levofloxacin-ketorolac combination was effective in bacterial eradication and well-tolerated in adults with moderate-to-severe ABC. These results suggest a possible positive levofloxacin-ketorolac interaction warranting further investigation in a phase III study."
Journal • Conjunctivitis • Ocular Infections • Ocular Inflammation • Ophthalmology
May 08, 2026
Does intracameral dexamethasone at the conclusion of routine cataract surgery decrease the incidence of post-operative complications?
(ARVO 2026)
- "Three surgeons used a postoperative regimen of immediate intracameral cefuroxime 1 mg plus topical dexamethasone 0.1% eye drops (Maxidex) four times daily for 3 weeks and ketorolac 0.5% (Acular) three times daily for 3 weeks. The findings suggest that the dexamethasone injection is safe and may offer benefits in the early recovery period, such as comfort and convenience, even if it does not change long-term outcomes. Larger studies on early patient experience may help determine whether it should become a routine part of cataract surgery care."
Surgery • Cataract • Macular Edema • Ocular Inflammation • Ophthalmology • Uveitis
January 22, 2026
INSPIRE: INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study
(clinicaltrials.gov)
- P1 | N=164 | Active, not recruiting | Sponsor: Stephen J. Kim, MD | Trial completion date: Dec 2025 ➔ May 2026 | Trial primary completion date: Dec 2025 ➔ May 2026
Trial completion date • Trial primary completion date • Diabetic Retinopathy • Retinal Disorders • CXCL8
July 23, 2025
Granulomatous Rosacea with Ocular Involvement: A Case Masquerading as Herpes Zoster Ophthalmicus
(EADV 2025)
- "An ophthalmologist prescribed ocular ketorolac for suspected keratitis...He had nodulocystic acne four years earlier, with good response to oral isotretinoin...Prednisone 40 mg/day for five days, acyclovir 800 mg five times daily for seven days, and intensive skin hydration were started...In such cases, 1% topical ivermectin is advised, and combination therapy may be required for resistant cases... ** This case highlights the need for accurate differential diagnosis and proper management of rosacea with ocular signs. Early intervention is critical when serious conditions like herpes zoster ophthalmicus are suspected. Antivirals with corticosteroids offered effective initial control, preventing complications."
Clinical • Acne Vulgaris • Atopic Dermatitis • Dermatology • Herpes Zoster • Immunology • Keratitis • Ocular Inflammation • Ophthalmology • Pruritus • Rosacea • Varicella Zoster
July 01, 2025
Incidence of and Risk Factors for Silicone Oil-Associated Cystoid Macular Edema After Pars Plana Vitrectomy.
(PubMed, J Vitreoretin Dis)
- "Compared with untreated groups, the frequency of CME regression was not influenced by the administration of sub-Tenon triamcinolone acetonide (75.0% vs 75.0%; P = 1.00), prednisolone acetate eyedrops (75.0% vs 75.0%; P = 1.00), or ketorolac eyedrops (71.4% vs 76.9%; P = .79). The viscosity of the SO used for vitreous tamponade in RD repair may play a role in the development of CME, with lighter grade oil increasing the risk for disease. Furthermore, SO removal alone potentially leads to a prominent reduction in CME in most cases."
Journal • Macular Edema • Ophthalmology • Retinal Disorders
March 28, 2025
Treatment of allergic rhinitis and allergic conjunctivitis.
(PubMed, Med Lett Drugs Ther)
- No abstract available
Journal • Allergic Rhinitis • Allergy • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology
December 10, 2024
Comparing the sedative and analgesic effects of ketorolac and diclofenac eye drops among patients with cataract surgery: A double-blind randomized clinical trial.
(PubMed, Oman J Ophthalmol)
- "Ketorolac eye drops are more effective than diclofenac eye drops in significantly reducing intraoperative pain among the candidates for CS with topical anesthesia. Therefore, ketorolac eye drops can be used with tetracaine eye drops in CS with topical anesthesia to produce greater perioperative analgesia and sedation."
Clinical • Journal • Surgery • Anesthesia • Cataract • Ophthalmology • Pain
December 03, 2024
Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma
(clinicaltrials.gov)
- P2 | N=82 | Terminated | Sponsor: Emory University | Phase classification: P1 ➔ P2 | Trial completion date: Oct 2024 ➔ Feb 2024 | Recruiting ➔ Terminated | Trial primary completion date: Oct 2024 ➔ Feb 2024; This study was terminated after interim analyses showed no benefits.
Biomarker • Phase classification • Surgery • Trial completion date • Trial primary completion date • Trial termination • Genito-urinary Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor
July 28, 2024
Nsaid-Induced Corneal Melt As The First Presentation Of Sjögren'S Syndrome Following An Uncomplicated Cataract Surgery
(ESCRS 2024)
- "Post-operative treatment included G. Acular (Ketorolac Tromethamine 0.5%, NSAID: non-steroidal anti-inflammatory drug) and G. Tobradex (Tobramycin 0.3% and Dexamethasone 0.1%, antibiotic and steroid respectively) each prescribed four times a day for two weeks. 4. The prescription of preservative-free eye drops is recommended, and topical NSAIDs should be prescribed judiciously or even avoided in patients with compromised ocular surfaces, considering the risk of corneal melt."
Surgery • Achromatopsia • Cataract • Dry Eye Disease • Macular Edema • Ophthalmology
September 03, 2024
INSPIRE: INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study
(clinicaltrials.gov)
- P1 | N=164 | Active, not recruiting | Sponsor: Stephen J. Kim, MD | N=264 ➔ 164
Enrollment change • Diabetic Retinopathy • Retinal Disorders • CXCL8 • IL6 • VEGFA
July 12, 2024
CES-NSLT: Efficacy of NSAID vs. Steroid-NSAID Combo Post-Selective Laser Trabeculoplasty: Phase 4, Single-Center RCT
(clinicaltrials.gov)
- P4 | N=126 | Not yet recruiting | Sponsor: St. Joseph's Healthcare Hamilton
New P4 trial • Cardiovascular • Glaucoma • Inflammation • Ophthalmology
May 24, 2024
NSAID-induced corneal melt as the first presentation of Sjögren's syndrome.
(PubMed, BMJ Case Rep)
- "Postoperative treatment included G. Acular (Ketorolac Tromethamine 0.5%, NSAID: non-steroidal anti-inflammatory drug) and G. Tobradex (Tobramycin 0.3% and Dexamethasone 0.1%, antibiotic and steroid, respectively) each prescribed four times a day for 2 weeks. On investigation, the patient had positive anti-RO and anti-LA antibodies, suggesting a diagnosis of Sjögren's syndrome. We advocate for careful preoperative assessment prior to cataract surgery, patient education, close follow-up and cautious medication use postoperatively including avoiding NSAID drops in patients with risk factors for postoperative dry eye disease."
Journal • Achromatopsia • Cataract • Dry Eye Disease • Immunology • Ophthalmology • Rheumatology • Sjogren's Syndrome • Transplantation
March 06, 2024
INSPIRE: INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study
(clinicaltrials.gov)
- P1 | N=264 | Active, not recruiting | Sponsor: Stephen J. Kim, MD | Recruiting ➔ Active, not recruiting
Enrollment closed • Diabetic Retinopathy • Retinal Disorders • CXCL8 • IL6 • VEGFA
January 23, 2024
Neurotrophic Keratopathy after wide retinal endolaser and postoperative Ketorolac eye drops: A case series.
(PubMed, Eur J Ophthalmol)
- "Postoperative Ketorolac eye drops, in patients who underwent PPV with endolaser, may reduce the corneal sensitivity, predispose to epithelial disruption and NK development. Studies are needed to explore the effect of NSAIDs on corneal sensitivity reduction in patient who will undergo PPV and extensive endolaser."
Journal • Diabetes • Dry Eye Disease • Keratitis • Metabolic Disorders • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders
November 12, 2023
Preparation of Polycaprolactone and Polymethacrylate Nanofibers for Controlled Ocular Delivery of Ketorolac tromethamine: Pharmacokinetic study in Rabbit's Eye.
(PubMed, Eur J Pharm Sci)
- "Acceptable cell viability confirmed the safety of inserts. Due to the fact that this preservative-free polymer insert can obtain therapeutic concentration in the tear film without fluctuation, it can be a suitable alternative for the treatment of intraocular inflammations with less complications, easier use, and even higher intraocular penetration."
Journal • PK/PD data • Preclinical • Allergy • Immunology • Inflammation • Ocular Inflammation • Ophthalmology
October 24, 2023
Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma
(clinicaltrials.gov)
- P1 | N=76 | Recruiting | Sponsor: Emory University | Trial completion date: Sep 2023 ➔ Oct 2024 | Trial primary completion date: Sep 2023 ➔ Oct 2024
Biomarker • Surgery • Trial completion date • Trial primary completion date • Genito-urinary Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • CSF2 • CXCL8 • IL10 • IL1A • IL1B • IL2 • IL6 • TNFA
September 09, 2023
Preformulation-Assisted Design of Ketorolac Tromethamine for Effective Ophthalmic Delivery.
(PubMed, J Ocul Pharmacol Ther)
- "Being a weak ionizable drug, both water and lipid solubility, as measured through partition coefficients, it demonstrated pH-dependency. For the optimum balance of water and lipid solubility required for penetration through the lipophilic corneal epithelial barrier, ketorolac eye drops would be better formulated between pH 5.5 and 6.6 than being formulated at the physiological fluid pH 7.4, where the drug is extremely hydrophilic and less permeable."
Journal • Conjunctivitis • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Pain
July 15, 2023
Formulation and In-Vitro/Ex-Vivo Characterization of Pregelled Hybrid Alginate-Chitosan Microparticles for Ocular Delivery of Ketorolac Tromethamine.
(PubMed, Polymers (Basel))
- "Conclusively, the cytotoxicity assay confirmed that the investigated MPs were non-irritant and could confer protection from direct drug irritation of KT on the ocular surface. The MTT cytotoxicity assay confirmed that KT-loaded MPs showed acceptable and reasonable tolerability with both human lens and corneal epithelial cell lines compared to the control samples."
Journal • Preclinical
May 03, 2023
Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma
(clinicaltrials.gov)
- P1 | N=76 | Recruiting | Sponsor: Emory University | Trial completion date: Apr 2023 ➔ Sep 2023
Trial completion date • Genito-urinary Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • CSF2 • CXCL8 • IL10 • IL1A • IL1B • IL2 • IL6 • TNFA
March 12, 2023
TOPICAL NSAID INDUCED CORNEAL MELT: A CASE REPORT
(ESCRS-WM 2023)
- "She was commenced on topical Maxitrol (dexamethasone, polymyxin B sulphate, neomycin sulphate) and Acular (Ketorolac) QDS post-operatively. This case highlights the importance of awareness of the major side effect of topical NSAIDs. It is essential to identify patient cohorts at risk pre-operatively to avoid adverse outcomes, particularly those with pre-existing ocular surface disease."
Clinical • Corneal Abrasion • Ophthalmology
October 12, 2022
Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma
(clinicaltrials.gov)
- P1 | N=76 | Recruiting | Sponsor: Emory University | Trial completion date: Aug 2022 ➔ Apr 2023 | Trial primary completion date: Aug 2022 ➔ Apr 2023
Biomarker • Trial completion date • Trial primary completion date • Genito-urinary Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • CSF2 • CXCL8 • IL10 • IL1A • IL1B • IL2 • IL6 • TNFA
October 10, 2021
Effect of preoperative eyedrops on cytokine concentrations in aqueous humor of patients undergoing femtosecond laser-assisted cataract surgery.
(PubMed, Graefes Arch Clin Exp Ophthalmol)
- "Preoperative fluorometholone instillation reduced IL-8, and ketorolac tromethamine instillation reduced IL-8 and PGE, in aqueous humor of patients undergoing femtosecond laser surgery, with the combination of both eyedrops being more effective than either alone."
Clinical • Journal • Cataract • Immunology • Inflammation • Oncology • Ophthalmology • CXCL8 • IL6 • TNFA
July 19, 2021
Role of Clapiks in Myopic Overcorrection Post LASIK and PRK
(ASCRS-ASOA 2021)
- "The extended wear contact lenses of low Dk value was changed on weekly basis .ResultsThe average spherical equivalent of the 8 patients at 1 week postop was +1.50 D with the use of Acular and the soft contact lens. The average postop spherical equivalent at 1 month postop was +0.75 D. The mean regression with the use of ketorolac was +0.50 D. No side effects or complications were noted with the use of ketorolacConclusionThe use of ketorolac and soft contact lenses appears to be safe and effective for reducing small amounts of hyperopia in the postop myopic LASIK and PRK patients. CLAPIKS may be used clinically to avoid additional surgery for overcorrection."
1 to 25
Of
128
Go to page
1
2
3
4
5
6